China’s pharmaceutical landscape is currently under transformation, with domestic biosimilars playing an increasingly pivotal role in cancer treatment. With healthcare budgets tightening and patient loads increasing, cost-efficiency and effective treatment options take center stage in medical strategies. This study explores the cost-effectiveness of domestic bevacizumab biosimilars compared to established originator treatments, a vital step for improving cancer care accessibility and affordability for affected populations.
Study Objective and Methods
Researchers conducted an evaluation focusing on three domestic biosimilars—IBI305, LY01008, and QL1101—and an originator biopharmaceutical, Avastin as frontline treatments for nonsquamous non-small cell lung cancer (NSCLC). To analyze their cost-effectiveness, the team applied a network meta-analysis with fractional polynomial methods, hence bypassing traditional proportional hazards assumptions. This approach facilitated a realistic comparison of overall survival (OS) and progression-free survival (PFS). Furthermore, a partitioned survival model compared the biosimilars’ efficacy and costs against the originator, integrating essential cost, utility parameters, as well as data scaling from prior investigations.
Results Analysis
Within the study, the combination of IBI305 biosimilar with chemotherapy emerged as the most effective over its counterparts, delivering cost savings along with beneficial health outcomes. LY01008 stood out with an extra 0.23 QALYs and a higher cost of $817, resulting in an incremental cost-effectiveness ratio (ICER) of $3,552/QALY versus QL1101. The findings suggested all three biosimilars as favorable in cost-effectiveness over the originator. Deterministic and probabilistic sensitivity analyses pinpointed that hazard ratio parameters from the meta-analysis and drug costs drove uncertainty in incremental net monetary benefits.
Insights drawn include:
- IBI305 displays the highest cost-effectiveness potential in most scenarios.
- Sensitivity analyses reinforce the validity of study results.
- LY01008 offers a moderate cost increase for mild QALY gains.
- Drug pricing remains a crucial factor influencing economic viability.
China offers promising pathways toward reducing NSCLC treatment costs, as evidenced by domestic bevacizumab biosimilars potentially achieving more cost-effective outcomes compared to international originators. The study’s insightful findings support robust considerations for integrating domestic biosimilars into clinical settings, thereby amplifying patient access to essential cancer treatments. Armed with these insights, healthcare policymakers can make informed decisions, enhancing treatment affordability and outcomes in the face of economic constraints and growing cancer incidence rates.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
